UCSF researchers in collaboration with the Centers for Disease Control’s Tuberculosis Trials Consortium and the AIDS Clinical Trials Group published a landmark study this May in the New England Journal of Medicine that demonstrated a new four-month treatment regimen for tuberculosis (TB) was safe and as efficacious as the standard six-month therapy. UCSF researchers and their partners are the first to accomplish this feat in over 40 years.
- New England Journal of Medicine study, May 2021
- “Shortening the Short Course of Tuberculosis Treatment”, NEJM Editorial
- WHO’s Guideline Development Group Rapid Communication Endorsement
- CDC Letter to Colleagues
- National Institute of Allergy and Infectious Diseases (NIAID), “Landmark TB Trial Identifies Shorter-Course Treatment Regimen”
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens (S31/A5349) Clinical Trials page
- UCSF press release
- Data-driven drug dosing speeds tuberculosis treatment to four months", UCSF School of Pharmacy, August 2021.